Dietary eicosapentaenoic acid and docosahexaenoic acid from fish oil. Their incorporation into advanced human atherosclerotic plaques
- PMID:1829632
- DOI: 10.1161/01.atv.11.4.903
Dietary eicosapentaenoic acid and docosahexaenoic acid from fish oil. Their incorporation into advanced human atherosclerotic plaques
Abstract
The incorporation of fatty acids from dietary fish oil was measured in obstructive atherosclerotic plaques removed from 11 patients fed fish oil, rich in omega-3 fatty acids, for 6-120 days before a planned arterial endarterectomy. The fatty acids of plasma and atheroma were analyzed with special reference to docosahexaenoic acid (DHA, 22:6) and eicosapentaenoic acid (EPA, 20:5), the principal omega-3 fatty acids of fish oil. The omega-3 fatty acid content increased greatly in plasma from 0.9% of fatty acids to 14.8% in cholesteryl esters, from 3.8% to 22.1% in phospholipids, and from 1.3% to 21.9% in triglycerides. The omega-3 fatty acid content of the atherosclerotic plaques was also greater when compared with that of plaques removed from 18 non-fish oil-fed controls. The omega-3 fatty acid in cholesteryl esters of the plaques was 4.9% in the experimental group versus 1.4% in control plaque, in phospholipids it was 8.8% versus 1.8%, and in triglycerides it was 4.7% versus 0.7% (p less than 0.001 for each lipid class). The two major omega-3 fatty acids (DHA and EPA) behaved differently. Compared with their respective plasma levels, relatively more DHA than EPA was deposited into the plaques. Whereas the increase of omega-3 fatty acids in plasma reached a plateau 3 weeks after initiation of fish oil feeding, a linear increase in plaque omega-3 fatty acids continued with time. As a result of the changes in fatty acid composition, the lipid classes of both plasma and plaque had a higher unsaturation index in the fish oil-fed group.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
- Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men.Vidgren HM, Agren JJ, Schwab U, Rissanen T, Hänninen O, Uusitupa MI.Vidgren HM, et al.Lipids. 1997 Jul;32(7):697-705. doi: 10.1007/s11745-997-0089-x.Lipids. 1997.PMID:9252957Clinical Trial.
- Alpha-linolenic acid in rapeseed oil partly compensates for the effect of fish restriction on plasma long chain n-3 fatty acids.Valsta LM, Salminen I, Aro A, Mutanen M.Valsta LM, et al.Eur J Clin Nutr. 1996 Apr;50(4):229-35.Eur J Clin Nutr. 1996.PMID:8730609Clinical Trial.
- Effect of fish oils containing different amounts of EPA, DHA, and antioxidants on plasma and brain fatty acids and brain nitric oxide synthase activity in rats.Engström K, Saldeen AS, Yang B, Mehta JL, Saldeen T.Engström K, et al.Ups J Med Sci. 2009;114(4):206-13. doi: 10.3109/03009730903268958.Ups J Med Sci. 2009.PMID:19961266Free PMC article.
- Omega-3 fatty acids for nutrition and medicine: considering microalgae oil as a vegetarian source of EPA and DHA.Doughman SD, Krupanidhi S, Sanjeevi CB.Doughman SD, et al.Curr Diabetes Rev. 2007 Aug;3(3):198-203. doi: 10.2174/157339907781368968.Curr Diabetes Rev. 2007.PMID:18220672Review.
- Marine lipids: overview "news insights and lipid composition of Lyprinol".Sinclair AJ, Murphy KJ, Li D.Sinclair AJ, et al.Allerg Immunol (Paris). 2000 Sep;32(7):261-71.Allerg Immunol (Paris). 2000.PMID:11094639Review.
Cited by
- Understanding resolvin signaling pathways to improve oral health.Keinan D, Leigh NJ, Nelson JW, De Oleo L, Baker OJ.Keinan D, et al.Int J Mol Sci. 2013 Mar 8;14(3):5501-18. doi: 10.3390/ijms14035501.Int J Mol Sci. 2013.PMID:23528855Free PMC article.
- Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.Mozaffarian D, et al.JAMA. 2012 Nov 21;308(19):2001-11. doi: 10.1001/jama.2012.28733.JAMA. 2012.PMID:23128104Free PMC article.Clinical Trial.
- The ω-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation trial--rationale and design.Mozaffarian D, Marchioli R, Gardner T, Ferrazzi P, O'Gara P, Latini R, Libby P, Lombardi F, Macchia A, Page R, Santini M, Tavazzi L, Tognoni G.Mozaffarian D, et al.Am Heart J. 2011 Jul;162(1):56-63.e3. doi: 10.1016/j.ahj.2011.03.035. Epub 2011 Jun 12.Am Heart J. 2011.PMID:21742090Free PMC article.Clinical Trial.
- The Benefits of Omega-3 Fats for Stabilizing and Remodeling Atherosclerosis.DiNicolantonio JJ, O'Keefe JH.DiNicolantonio JJ, et al.Mo Med. 2020 Jan-Feb;117(1):65-69.Mo Med. 2020.PMID:32158053Free PMC article.Review.
- Docosahexanoic acid-induced coronary arterial dilation: actions of 17S-hydroxy docosahexanoic acid on K+ channel activity.Li X, Hong S, Li PL, Zhang Y.Li X, et al.J Pharmacol Exp Ther. 2011 Mar;336(3):891-9. doi: 10.1124/jpet.110.176461. Epub 2010 Dec 14.J Pharmacol Exp Ther. 2011.PMID:21156816Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials